KLRS (Kalaris Therapeutics) Inventories, Finished Goods: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRS Kalaris Therapeutics Inc KLRS
12 GF Score
Price $3.97
View Full Analysis

What is Kalaris Therapeutics Inventories, Finished Goods?

Kalaris Therapeutics KLRS +0.76% 12 Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus rates KLRS with a GF Score™ of 12/100.

Kalaris Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Kalaris Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kalaris Therapeutics Inventories, Finished Goods Chart

Kalaris Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
0.00 0.00 0.00 0.00

Kalaris Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KLRS
12GF Score
Kalaris Therapeutics Inc KLRS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kalaris Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Kalaris Therapeutics (KLRS) has a Inventories, Finished Goods of $0.00 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Kalaris Therapeutics and its competitors.
Is Kalaris Therapeutics' Inventories, Finished Goods too high?
Kalaris Therapeutics' current Inventories, Finished Goods is $0.00 Mil. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' Inventories, Finished Goods compare to HRTX and VRCA?
Kalaris Therapeutics' Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Kalaris Therapeutics and its competitors. Kalaris Therapeutics's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kalaris Therapeutics Business Description

Address 400 Connell Drive, Suite 5500, Berkeley Heights, NJ, USA, 07922
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score

Get the complete analysis for KLRS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price